|
Aprea Therapeutics Inc (NASDAQ: APRE) |
|
Aprea Therapeutics Inc
APRE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Aprea Therapeutics Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Aprea Therapeutics Inc net loss increased from $-3 millions, to $-4 millions in first quarter of 2025,
• More on APRE's Growth
|
|
Aprea Therapeutics Inc realized a net loss in trailing twelve months.
Aprea Therapeutics Inc realized cash reduction of $ -2.18 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 7.34.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
• More on APRE's Valuation
|
|
|
|
|
Aprea Therapeutics Inc realized net loss in trailing twelve months.
Aprea Therapeutics Inc realized cash outflow of $ -2.18per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 7.34.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
Aprea Therapeutics Inc Price to Book Ratio is at 0.71 lower than Industry Avg. of 33.33. and higher than S&P 500 Avg. of 0.01
• More on APRE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com